home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408c.zip
/
M9480653.TXT
< prev
next >
Wrap
Text File
|
1994-08-20
|
2KB
|
38 lines
Document 0653
DOCN M9480653
TI [Ansatipine: only preventive treatment available for opportunistic MAI
infections in AIDS. From an interview with Dr. Agnes Mignon]
DT 9410
AU Mignon A; Laboratoires Pharmacia, Saint-Quentin-en-Yvelines.
SO Allerg Immunol (Paris). 1994 Apr;26(4):148, 151-3. Unique Identifier :
AIDSLINE MED/94304498
AB Ansatipine, the international name of which is rifabutine, is a new
specialty that was licensed in February 1993 and marketed in France in
June 1993. It is an antibiotic of the rifamycin family, the result of
research by Farmitalia Carlo Erba and is now presented by the
Laboratoire Pharmacia. Today, rifabutine is the only molecule in the
world that has been shown to be efficacious in preventative treatment
for infections by the Mycobacterium avium complex (MAC) and to be
officially recognised as such. Rifabutine (Ansatipine) was developed for
prophylaxis of infections by MAC, because of its bacteriological
activity on mycobacteria and especially on the Mycobacterium avium
complex, the small number of the MAC which are naturally resistant, its
high degree of tissue and intracellular penetration and its long
half-life that allows a single daily dose. Clinical tests on more than
1,000 patients have shown the benefit of Ansatipine in the prophylactic
treatment of MAC infections: reduction by half on the frequency of
surveillance, prolongation of the delay in appearance, significant
improvement in general condition and quality of life of the patients.
Ansatipine is now dispensed to town pharmacies, which can only ease the
daily lives of patients and reinforce the co-operation between hospital
teams and general practitioners who specialize in the care of AIDS.
DE AIDS-Related Opportunistic Infections/MICROBIOLOGY/*PREVENTION &
CONTROL Clinical Trials English Abstract Human Mycobacterium
avium-intracellulare Infection/*PREVENTION & CONTROL Pharmacies
Quality of Life Rifabutin/PHARMACOKINETICS/SUPPLY &
DISTRIBUTION/*THERAPEUTIC USE INTERVIEW JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).